WE ARE INNOVATIVE
Bonti is a clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications. We are developing a first-in-class pipeline of proprietary product candidates derived from botulinum neurotoxin serotype E, or BoNT/E. BoNT/E has a validated mechanism of action similar to that of currently approved products derived from botulinum neurotoxin serotype A, or BoNT/A. Our product candidates have been observed to have a faster onset of efficacy and a shorter duration of activity than BoNT/A products based on preclinical and clinical data to date. We believe that this clinical profile will enable BoNT/E products to address unmet therapeutic and aesthetic needs.
OUR CORE VALUES AND CULTURE
- Staying unwaveringly focused on patients to deliver on our promises with compassion and accountability, yet resilient enough to bounce back from adversity to emerge stronger.
- Pursuing validated, data-driven, impactful science, mixed with passion, open-mindedness, and disruptive creativity to drive breakthrough innovation.
- Acting methodically and thoughtfully to plan our desired outcomes and take smart risks, yet efficiently, so we can move fast and make things happen without wasting time.
- Abiding by uncompromising ethical principles like integrity, honesty, respect, loyalty, and doing the right thing, coupled with a good sense of humor and playfulness to have fun.
- Possessing boundless ambition as a company to make a difference in the world, yet humble coachabilityas individuals to learn, grow, and invest in our team’s development.
BOARD OF DIRECTORS
Jonathan E. Lim, M.D.
Jonathan E. Lim, M.D. has served on our board of directors since February 2016. Dr. Lim is a co-founder of our company and joined our board as Chairman in February 2016. Dr. Lim has been President, Chief Executive Officer, and Co-Founder of Ignyta, Inc. (Nasdaq: RXDX) since July 2012, which he co-founded in August 2011, and served as Chairman from Ignyta’sinception to the completion of its acquisition by Roche in February 2018. Dr. Lim is also a member of the Board of Visitors of the MooresCancer Center at the University of California, San Diego, a position he has held since December 2015. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a private biotechnology company that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd., an Australian public biotechnology company, in September 2012. Dr. Lim served as a member of the board of directors of Bionomics Ltd. until November 2015. Prior to founding Eclipse Therapeutics, Dr. Lim served as the President, Chief Executive Officer and a Director of HalozymeTherapeutics from May 2003 to December 2010. Prior to that, Dr. Lim’s experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University and an M.P.H. from Harvard University.
Thomas A. Albright, M.B.A.
Thomas A. Albright, M.B.A. has served on our board of directors since February 2016. Mr. Albright has served as President and Chief Executive Officer of Recros Medica, Inc., a private development stage medical aesthetic device company, since September 2017. Mr. Albright was formerly Chairman and Chief Executive Officer of Andrew Technologies LLC from 2011 to August 2017. Previously, Mr. Albright was President of the topical aesthetic division at Syneron Medical Ltd. and before that, Head of North American marketing at Nobel Biocare. From 2000 to 2008, Mr. Albright was at Allergan, where he led the U.S. and Global launches of Botox Cosmetic and the commercial development of Latisse, and was VP Botox Global Strategic Marketing since 2003. He started his medical industry experience in 1983 at the Parke-Davis division of Warner Lambert, where he was a Director of Marketing on the Lipitor launch team. Mr. Albright is also a board member of Andrew Technologies, LLC and a board director of Recros Medica, private medical technology companies. Mr. Albright has a B.S. in Biology from The Citadel and an M.B.A. in Marketing from Mercer University.
Jacob Chacko, M.D.
Jacob Chacko, M.D. has served as a member of our board of directors since February 2018. Dr. Chacko previously served as Chief Financial Officer of Ignyta, Inc. (Nasdaq: RXDX) from May 2014 to March 2018. Ignyta became a wholly owned subsidiary of Roche in February 2018. Dr. Chacko joined Ignyta from TPG Capital, a global private investment firm with approximately $80 billion of assets under management, where he served as Vice President focused primarily on healthcare and digital media since August 2008. At TPG, Dr. Chacko helped lead teams that successfully completed acquisitions having an aggregate value of over $10 billion. He served on the boards of directors of RentPath Inc. and EnvisionRx, was an advisor to the audit committee of Par Pharmaceutical, Inc. and was a board observer to IMS Health and Quintiles Transnational. Dr. Chacko previously served on the Board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford and is Chairperson of the Western Regional Selection Committee for the Marshall Scholarship. Prior to TPG, Dr. Chacko concurrently received his M.D. with AOA honors from UCLA and his M.B.A. with Distinction from Harvard Business School, and was president of his class at both institutions. Prior to this, Dr. Chacko was a consultant serving healthcare clients at McKinsey & Company, a management consulting firm. Dr. Chacko received a M.Sc. in economic and social history from Oxford University, where he was a Marshall Scholar, and a B.A. in Biology, B.S. in Gerontology, and minor in Health Policy and Management from the University of Southern California, where he graduated as the University Valedictorian.
Fauad Hasan is a co-founder and has served as our President and Chief Executive Officer and member of our board of directors since June 2015. Prior to that, from June 2008 to May 2015, Mr. Hasan served as the Strategic and Technical Lead for Biologics programs at Allergan, which include next generation neurotoxin molecules. During his time at Allergan, Mr. Hasan served in various roles with increasing responsibilities in the areas of R&D, Manufacturing/Supply Chain Operations, Program Management and Business Development. Mr. Hasan has over 16 years of experience, which includes positions of increasing responsibilities at companies like Regeneron and Baxter. Mr. Hasan received his B.S. in Chemical Engineering from California State University, Long Beach, and his M.S. and his M.B.A. from the University of Maryland.
Dennis Huang has served on our board of directors since February 2016. Mr. Huang joined Ultragenyx Pharmaceutical Inc. in May 2015 and is currently Chief Technical Operations Officer and Executive Vice President, where he is responsible for leading the process development, manufacturing, and supply chain distribution functions and is a member of the executive leadership team. Previously, Mr. Huang was the Senior Vice President of Manufacturing and Supply Chain for InterMune Incorporated from August 2013 to March 2015 where he led the global manufacturing organization and supply chain activities for the company. From May 2006 to August 2013, Mr. Huang served as the Vice President of Biologics Manufacturing and Development for Allergan, Inc. During his 7-year tenure at Allergan, he improved the commercial manufacturing performance and expanded the biologics development capability, which resulted in a rapid expansion of the biologics pipeline. Earlier in his career, Mr. Huang held several positions at Novartis AG (formerly Chiron, Inc.), Genentech, Inc., and Synergen (currently Amgen), where he worked in a number of roles including manufacturing, quality, and process development. Mr. Huang holds a B.A. in Chemistry from Knox College in Galesburg, Illinois.
Alexey Konov, Ph.D.
Alexey Konov, Ph.D. has served on our board of directors since December 2016. Dr. Konov is the founding partner of RBV Capital, a venture capital fund investing in early-stage biotechs globally, which was founded in October 2014. In 2015, RBV Capital co-led the B-round investment in Retrosense Therapeutics where Dr. Konov served as a board member until the successful sale to Allergan in 2016. From February 2014 to October 2014, Dr. Konov was a partner at RusBio Ventures LLC, a venture investment company. From January 2013 to January 2014, Dr. Konov served as head of venture capital for R-Pharm Ventures LLC, a venture investment company. In the past, Dr. Konov served as VP at Bioprocess Holding, where he was responsible for formation of its early biotech portfolio. He then started a captive venture fund Bioprocess Capital and served as its investment director and board member of the fund’s portfolio companies in Russia, the EU and the United States. Prior to that, Dr. Konov worked for Monsanto Company as a consultant, progressing to country scientific outreach lead at Monsanto Russia. Dr. Konov received a degree in Physiology from the Moscow State University in 1989 and received a Ph.D. degree in Molecular Biology from Louis Pasteur University (France) in 1998.